Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00148083 · ClinicalTrials.gov registry record · Phase 3
Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia
A Phase 3 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 3
- Development phase
- 5
- Enrollment target
NCT00148083 is a Phase 3 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 5 participants.
The verdict
NCT00148083, a Phase 3 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5 participants
- Enrollment target
Study Summary
The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the ability to benefit from skills training interventions among schizophrenia patients. The primary objective of this study is to compare patients on Risperdal Consta to patients on other atypical antipsychotic medications in terms of their ability to benefit from skills training interventions. A secondary objective of this study is to determine whether patients taking Risperdal Consta improve in other areas of cognitive functioning and social functioning.
Interventions
- BEHAVIORAL Social Skills Training
- DRUG Risperdal Consta (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00148083
The ClinicalTrials.gov registry entry for NCT00148083 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Social Skills Training is the first listed.
NCT00148083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00148083 about?
NCT00148083 is a clinical study titled "Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia". The specific aim of this study is to determine whether the new, long-acting, form of risperidone, Risperdal Consta, improves the ability of schizophrenia patients to benefit from skills training. The hypothesis guiding this study is that Risperdal Consta, by improving verbal memory, will improve the...
What is the current status of trial NCT00148083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5 participants. The study started on 2005-09. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00148083?
The interventions under investigation include: Social Skills Training (BEHAVIORAL), Risperdal Consta (drug) (DRUG).
Who is sponsoring clinical trial NCT00148083?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.